STAAR Shares Surge 44.8% on Alcon's $28 Acquisition Offer

Introduction

STAAR Surgical Company (NASDAQ: STAA) is a California-based medical device manufacturer specializing in implantable phakic intraocular lenses (ICLs) for myopia, hyperopia, and astigmatism. Founded in 1982 and headquartered in Lake Forest, the company’s core product lines—Visian ICL and EVO ICL™—offer a minimally invasive, reversible alternative to glasses or contact lenses.

Corporate Structure and Operations

STAAR Surgical employs approximately 900 people across research, development, manufacturing, and packaging facilities in Aliso Viejo and Monrovia, California, and Nidau, Switzerland. The company has marketed over 3,000,000 ICLs in more than 75 countries, dedicating over 40 years solely to ophthalmic surgery.

ICL surgery by Olga Kononenko

Developments and News

• August 5, 2025: STAAR filed a definitive proxy (DEFA14A) outlining its agreement to be acquired by Alcon Research, LLC for $28.00 per share in cash.
• The $28.00 offer represents a 51% premium over the closing price on August 4, 2025, and a 59% premium over the 90-day volume-weighted average price.
• The transaction is expected to close within six to twelve months, subject to shareholder and regulatory approvals, after which STAAR will become a wholly owned subsidiary of Alcon and delist from NASDAQ.
• August 6, 2025: STAAR plans to release financial results for the second quarter ended June 27, 2025; no conference call will be hosted due to the pending acquisition.

Financial and Strategic Analysis

On August 5, 2025, STAA shares closed at $26.77, reflecting an increase of 44.78% on a trading volume of 5,465,464 shares. Key metrics (TTM) include:

• Revenue: $279.1 million
• Net loss: $71.1 million (–25.5% profit margin)
• EPS: –$1.44
• Total cash: $222.8 million; Debt/Equity: 10.5%
• Levered free cash flow: $10.7 million

Market capitalization stands near $910 million, with a 52-week trading range of $13.50–$41.00. Equity analysts have assigned an average “Sell” rating, with target prices ranging from $13.00 to $15.00. The acquisition offer by Alcon provides immediate financial value to shareholders and presents an opportunity to utilize Alcon’s global commercial platform and R&D resources to potentially accelerate the adoption of ICLs and product development.

Market Position and Industry Context

STAAR Surgical is recognized within the market for implantable phakic ICLs, differentiating itself from corneal-based refractive procedures such as LASIK, PRK, and SMILE through its proprietary biocompatible Collamer® material. The EVO ICL™, approved in multiple markets, is particularly indicated for patients who are not candidates for corneal laser surgery or who seek a reversible option. The phakic ICL segment continues to experience growth as refractive surgeons expand their offerings beyond laser modalities, supported by favorable safety profiles.

tl;dr

On August 5, 2025, STAAR Surgical agreed to be acquired by Alcon at $28.00 per share—a 51% premium over the prior close—resulting in a 44.8% one-day stock increase. The deal is expected to close within 6–12 months, which will lead to STAAR's delisting from NASDAQ and the integration of its ICL business into Alcon. Financial results for Q2 2025 are scheduled for release on August 6, 2025, and the combined company aims to accelerate ICL adoption worldwide under Alcon’s commercial infrastructure.